depth discussion of the viruses implicated in MS pathogenesis. We first consider viruses with the greatest evidence base, namely EpsteinBarr virus (EBV), human herpesvirus (HHV-6), VZV, human endogenous retroviruses (HERV) and then go on to describe the potential roles for "minor" viruses in MS. We focus on the connection between viruses and MS pathophysiology rather than its clinical progression, and we highlight the limitations of existing studies and possible future research directions.
| SEARCH METHODS AND SELECTION CRITERIA
The PubMed and Google Scholar databases were searched for articles published (or appeared "Epub ahead of print") between 1 January 2006 to 31 December 2016 and the bibliographies examined. For initial screening, "multiple sclerosis," "infectious cause," "virus" or "viral model" were applied through the Boolean operators "AND" and "OR". More specific terms were applied to different sections of the review based on their relevance. If and when an infectious agent had more than one name, all relevant search terms were applied. Priority was given to original research articles and systematic reviews/metaanalyses over case reports or hypothesis/viewpoint articles and the most recent papers as applicable. Some references prior to the above time period were included given their historical importance. Studies referring to paediatric MS, infectious agents other than viruses and those not published in English were excluded.
| EPSTEIN-BARR VIRUS (EBV)
There is a lively ongoing debate on the role of EBV, the prevailing MS infectious risk factor and MS pathogenesis. [19] [20] [21] One hypothesis suggests that MS is caused by a genetically predisposed deficiency in eliminating previous EBV infection; EBV then persistently accumulates or even establishes itself in the brains of such patients. 7, 22 Consistent with this theory, EBV might exercise a strong influence on the number of naïve and/or memory B cells and their differentiation status. 23 A competing hypothesis is that abnormal responses to EBV infection are secondary to and not a cause of MS. 24 At the epidemiological level, several systematic reviews clearly support an association between MS and EBV seropositivity. 3, 25, 26 Practically, all MS patients are EBV seropositive, raising the question of whether EBV-seronegative MS patients even exist. 27 EBV seropositivity confers double the risk of MS than infectious mononucleosis (IM) (OR=4.56 vs OR=2.17, respectively), 3 and IM appears to have a stronger genetic component than EBV infection. 28 However, the reasons for this difference in risk between EBV seropositivity and IM might be due to: (i) reporting bias for IM; (ii) the molecular sto- 24, 38 In neuroimaging studies, MRI (magnetic resonance imaging) markers of MS activity and grey matter atrophy were found to be associated with anti-EBV antibody levels. 39, 40 At the cellular level, CD8 + T cells specific for EBV lytic and latent antigens were more frequent in patients with active and inactive MS, respectively. 41 Deep sequencing of T-cell receptor-β genes ("immunosequencing") showed intrathecally enriched EBV-reactive CD8 + T cells that were specific to patients with MS. 42 Furthermore, in animal models using lymphocryptovirus (LCV), which is a close relative of EBV, LCV-infected B cells lost their ability to process the extrinsic pathogenic CD8 + T-cell epitope in myelin oligodendrocyte glycoprotein (MOG). In doing so, they cross-presented this epitope to auto-aggressive cytotoxic T lymphocytes, a reaction that can initiate an autoimmune reaction and demyelination. 43 With regard to humoral immunity, the high antibody titres against EBNA proteins in patients with MS might be due to intrathecal synthesis but it has yet to be clarified whether they result from high- 48 Dual infection with EBV types 1 and 2 is more common in patients with MS compared to single infection. 49 Mechanistically, EBV might act as an environmental trigger or by attacking the CNS. 50 With respect to the former, an EAE model with the murine EBV homologue gamma-herpesvirus 68 showed more pronounced MS-like clinicopathological features that were dependent on the latent life cycle of the virus. 51 There are a number of theories with regard to the latter mechanism of direct CNS destruction by the virus: ; (iv) the "mistaken self" hypothesis based on proteomic analyses shows a higher frequency of a peptide corresponding to an EBNA-1 region sharing homology with the N-terminus of αB-crystallin in patients with MS. 52 Overall, understanding these mechanisms paves the way for novel anti-MS strategies, notably EBV-specific adoptive immunotherapy.
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It is also mechanistically intriguing how EBV plays a role in both cancer-a disorder of cellular proliferation-and MS-a disease characterized by neuronal cell death; however, recent reports of a genetic overlap between the EBV-related Hodgkin lymphoma and MS could shed some light on this. 53, 54 In parallel, dogma that EBV cannot possibly be found in glial cells or neurons, the host immune response must remain the focus of studies, 53 or that EBV latency status underpins virus-mediated pathogenesis 24 should be re-examined in the light of recent observations that EBV can cause lytic infection in human primary neurons. 55 To summarize, in the context of discordance between the high rates of EBV infection vs low rates of MS worldwide, EBV is likely to be necessary but not sufficient to cause MS. 19 Future studies on shared polygenic risk from genomewide association studies on MS cases with those with markers of increased EBV levels (eg EBNA- 1 56 ) are likely to shed further light on such host-pathogen interactions.
| HUMAN HERPESVIRUS 6 (HHV-6)
A recent, inconclusive, non-systematic summary of evidence on the role of HHV-6 in MS 57 highlighted the need for a formal meta-analysis on this topic. Furthermore, although HHV-6 has been detected mostly in acute demyelinating brain lesions in MS, detection rates are highly variable (HHV-6 DNA in the CSF ranging from 3% to 46% of patients). 58 Additionally, other markers such as B-or T-cell reactivity, higher antibody responses or higher viral loads have not been consistently observed in MS patients' serum in different ethnic groups or prospective studies. 57, 59 Some specific single nucleotide polymorphisms (SNPs; eg in CD46
and MHC2TA) are strongly associated with active replication of HHV-6
and, together, with worse clinical prognosis in MS. 60 At the edge of such gene-environment interactions lie the HERVs (see below). One of their subtypes (HERV-K18) was shown to be activated by HHV-6A, mainly in cell lines productively infected with the virus and followed by those with latently infected virus. These observations reinforce the notion that there is a common HERV-mediated pathway downstream of viral infection in MS, 61 which might be therapeutically exploitable. 62 The marmoset (Callithrix jacchus) HHV-6 model has been used to study viral neurotropism. 63 Interestingly, in contrast to how the virus seems to gain entry to the human CNS via olfactory pathways, 64 findings in marmosets revealed that only those with intravenous (and not intranasal) inoculation of HHV-6A (and not HHV-6B) developed neurological disease. 63 Furthermore, in contrast to the global seroprevalence of >95% for HHV-6B, HHV-6A is more frequent in patients with MS than HHV-6B, which is certainly worthy of further investigation.
57
HHV-6A infection leads to apoptosis in the brain, induces autoimmunity in several ways 65 and activates antiviral genes in human astrocytes including some genes upregulated in MS. 66 
| VARICELLA ZOSTER VIRUS (VZV)
Varicella zoster virus (VZV)-induced encephalomyelitis is characterized by demyelination similar to that seen in MS, so VZV is suggested as an MS-triggering factor. 67 However, while some epidemiological studies reported no association between a history of varicella infection in childhood and MS risk, 68 others have observed an association, most notably for relapse-remitting (RR) and secondary progressive types. 69 A fourfold increase in MS risk in the year following herpes zoster infection has been observed in a region with a low MS prevalence. 70 Regrettably, serological and molecular studies have not helped much in this area. VZV seropositivity was not significantly higher in patients with MS vs controls in two studies. 71, 72 Moreover, while VZV DNA was identified in the CSF of patients with MS (particularly of RR type) in some studies, 73, 74 others failed to confirm these findings in the CSF, blood or in acute MS lesions. 58, [75] [76] [77] More consistently, however, are the observations that the high levels of VZV DNA in CSF and PBMCs during relapse ultimately disappear during clinical remission. 78, 79 Interestingly, the progressive MS type has been associated with VZV DNA at levels between those found during the relapse and remission periods of the RR-MS type. 79, 80 The median fraction of intrathecal VZV-specific IgG of total IgG can differentiate patients with MS from those with VZV reactivation (35-fold higher in the latter). 81 This observation implies that low-level infection is present in at least some MS cases. It also helps address whether or not VZV detection in MS is due to reactivated, previously latent VZV infection; that is, "centripetal infection" from the neural ganglia towards the CNS. 82 Another theory suggests that VZV in MS is purely epiphenomenal due to leakage from destroyed sensory neurons; however, experimental evidence is lacking. 83 Also, VZV has not been identified in "traditional" autoimmune diseases, implying a more specific connection with MS. 82 Finally, VZV antigens induced and maintained activity of HERVs in peripheral lymphocytes from patients with MS compared to controls; retroviruses, as explained below, are implicated as causal in MS. 84 
| HUMAN ENDOGENOUS RETROVIRUSES (HERV)
Although initially both were implicated in MS pathology since the 1980s, subsequent studies have continued to support a role for endogenous rather than exogenous retroviruses in MS. 85 HERVs were There is also an established body of evidence that the envelope protein of the "MS-associated retrovirus" (MSRV-Env) in the HERV-W family is causal for MS. 94 Initially observed in leptomeningeal cells, the MRSV-Env protein has been detected in MS plaques containing 
| CYTOMEGALOVIRUS (CMV)
The majority of epidemiological studies on CMV in MS are underpowered and inconclusive. 7, 116 Two synchronous but different metaanalyses suggested a protective role for CMV seropositivity in MS. 117, 118 At the molecular level, it seems that CMV is present in the CNS including in some MS cases, but both exacerbating and protective roles are proposed. 116 For example, CMV-and brain-specific B cells are correlated in patients with MS, 119 while concurrently CMV infection might indirectly exacerbate MS by inducing specific T cells with proinflammatory properties. 116 Conversely, some studies have shown that higher anti-CMV antibody titres in patients with MS are positively associated with improved MS-related neuroimaging and disability status markers. 120 In addition, human CMV-induced natural killer cell expansion reduces the risk of disability progression in patients with MS. 121 In animal models, cross-reactivity between human CMV peptide and MOG has been detected, while secondary CMV infection following vaccinia virus infection can worsen T-cell autoreactivity and white matter lesions. In contrast, murine CMV infection prior to Theiler's murine encephalomyelitis virus (TMEV) infection in the TMEV murine model of MS appears to improve symptoms both clinically (ie motor performance) and histologically (ie the severity of the inflammatory cell infiltrate). 122 Finally, CMV (betaherpesvirinae subfamily) and EBV (gammaherpesvirinae subfamily) might oppose each other with regard to the downstream immune cascade (the so-called "immune response competition"), which might explain their inverse epidemiological patterns in MS. 118 It has been also suggested that these herpesviridae viruses could both be required to elicit a "primate-specific autoimmune pathway". 116 
| MEASLES AND OTHER MORBILLIVIRUSES
The association between the measles virus and MS has been investigated for over 50 years, with MS postulated to be a host response to later measles infection. However, measles vaccination is not associated with MS, indicating that the measles virus is probably not connected with MS and supporting the evidence that measles vaccines are safe despite unjustified and well-publicized claims to the contrary. 123 However, it is worth mentioning that two CNS complications of measles virus infection manifest with features of demyelination: acute disseminated encephalomyelitis, a differential diagnosis of paediatric MS and the very rare subacute sclerosing panencephalitis. 124 To our knowledge, recent research in this area has focused on the association between virus-specific CSF-to-serum antibody indices (AIs) and MS, not on virus detection using molecular techniques. The
AIs for measles, rubella and VZV, which form the "MRZ reaction"-high-specificity markers for "ruling-in" MS (reviewed in 125 )-are twofold higher than that for EBV. 126 In particular, the measles AI is higher in patients with ≥6 lesions on MRI than those with fewer lesions in early MS. 127 Another study showed that antimeasles virus antibody titres in the serum and CSF of patients with MS increase according to the age and duration of the disease.
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The phylogenetically close rinderpest virus has not been shown to be demyelinating or even neurotropic in its ruminant hosts. Interestingly, axonal damage precedes demyelination, prompting questions on the role of inflammation and astrocytes as intermediate players. 130 
| LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV)
Lymphocytic choriomeningitis virus (LCMV) can affect the human CNS to cause paralysis and reduced consciousness. However, investigating its role in MS is more difficult due to low titres and short presence of LCMV in the CSF. 131 In our opinion, this might indicate a "hit-and-run" mechanism. On the other hand, recent in silico predictions show high sequence and structural similarity between LCMV's nucleoprotein and specific myelin basic protein (MBP) residues. 132 Murine models of chronic LCMV infection have given rise to two Nobel Prizes. 131 The virus is thought to activate microglia and astrocytes in the CNS via a TLR2-mediated cascade. 133 Moreover, LCMV blocks induction of type 1 interferon and consequential upregulation of HLA class II. This observation supports a potential virus-induced disturbance in the interferon-tumour necrosis factor balance, which is already known to trigger autoimmunity. 
| SAFFOLD VIRUS
Saffold virus (SAFV), a picornaviridae family member identified in 2007, was the first human virus in the Cardiovirus genus to be described. 138 SAFV has a seroprevalence of over 90% in the adult population and is known to cause infection early in life. 139 SAFV is associated with both enteric and extra-intestinal diseases and, due to homology with TMEV, is implicated in MS. 138 However, its ubiquity has created difficulties in deciphering any association between SAFV and MS. 17 SAFV was not detected in CSF samples from patients with MS. 138 One hypothesis is that SAFV might cause low-grade persistent infection followed by inflammation rather than act as a "hit-and-run" trigger for autoimmunity. However, a recent study failed to find any SAFV in MS brains and only rare SAFV-specific oligoclonal bands in patients with MS and not different from controls. 17 
| LIMITATIONS OF EXISTING DATA
Several methodological issues could explain the described inconsistencies between studies in the MS-virus arena: (i) not choosing appropriate healthy matched controls following a specific study design but instead samples simply available at the time of study (ie an "op- 
